6-FABA

CAS No. 434-76-4

6-FABA( 6-Fluoroanthranilic Acid )

Catalog No. M14483 CAS No. 434-76-4

6-FABA (6-Fluoroanthranilic Acid) is a small-molecule inhibitor of MTB tryptophan synthesis that converts Mtb into a tryptophan auxotroph and restores the efficacy of a failed host defense.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G 27 Get Quote

Biological Information

  • Product Name
    6-FABA
  • Note
    Research use only, not for human use.
  • Brief Description
    6-FABA (6-Fluoroanthranilic Acid) is a small-molecule inhibitor of MTB tryptophan synthesis that converts Mtb into a tryptophan auxotroph and restores the efficacy of a failed host defense.
  • Description
    6-FABA (6-Fluoroanthranilic Acid) is a small-molecule inhibitor of MTB tryptophan synthesis that converts Mtb into a tryptophan auxotroph and restores the efficacy of a failed host defense; has an MIC of 5 uM in liquid broth in the absence of tryptophan in Pseudomonas aeruginosa.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    6-Fluoroanthranilic Acid
  • Pathway
    GPCR/G Protein
  • Target
    Antibacterial
  • Recptor
    Antibacterial
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    434-76-4
  • Formula Weight
    155.13
  • Molecular Formula
    C7H6FNO2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (644.62 mM)
  • SMILES
    C1=CC(=C(C(=C1)F)C(=O)O)N
  • Chemical Name
    2-Amino-6-fluorobenzoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang YJ, et al. Cell. 2013 Dec 5;155(6):1296-308.
molnova catalog
related products
  • Delamanid

    A mycolic acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against tuberculosis.

  • GSK-2140944

    GSK-2140944 (Gepotidacin) is a novel potent, selective bacterial type II topoisomerase inhibitor in development for the treatment of conventional and biothreat pathogens.

  • DS-2969b

    DS-2969b (DS 11960558) is a novel orally active GyrB inhibitor, inhibits the supercoiling activity of C. difficile DNA gyrase with IC50 of 20 ng/mL.